摘要
沙库巴曲缬沙坦是全球近年来慢性心力衰竭(HF)治疗领域具有突破性的创新药物,它是一种血管紧张素受体-脑啡肽酶抑制剂,可同时抑制肾素-血管紧张素-醛固酮系统并调节利钠肽系统。已被证实为目前首个也是唯一一个较标准治疗显著改善HF患者预后的药物,较依那普利能够显著改善射血分数,降低HF患者的死亡风险及再入院率,目前已被各国HF治疗指南推荐为慢性HF的一线治疗药物。后续更多研究表明,沙库巴曲缬沙坦还有逆转心脏重构、保护肾功能、降低血糖等作用,临床应用范围更加广泛,是应该大力推广的抗HF药物。本文将对沙库巴曲缬沙坦治疗HF的最新研究进展做一综述。
As an innovative drug in the field of chronic heart failure treatment worldwide in recent years,sacubitril-valsartan is a combination drug that contains the neprilysin inhibitor sacubitril and angiotensin receptor blocker valsartan. In the PARADIGM-HF trial, sacubitril/valsartan significantly reduced the primary endpoint of cardiovascular mortality and heart failure hospitalization, compared with enalapril.The rate of all-cause mortality was also significantly reduced. Subsequently, the European Society of Cardiology and American College of Cardiology/American Heart Association/Heart Failure Society of America recently have updated guideline recommendations for heart failure with reduced ejection fraction to recommend sacubitril/valsartan. This manuscript reviews new research of sacubitril/valsartan in heart failure.
作者
张䶮
范延红
孙冬冬
ZHANG Yan;FAN Yan-hong;SUN Dong-dong(Graduate School,Xijing Hospital,Air Force Medical University,Xi’an 710032,Shaanxi,China;Department of Cardiology,Xijing Hospital,Air Force Medical University,Xi’an 710032,Shaanxi,China)
出处
《心脏杂志》
CAS
2020年第2期193-196,共4页
Chinese Heart Journal
基金
西京医院助推计划项目资助(XJZT19ML54)。
关键词
心力衰竭
沙库巴曲缬沙坦
心脏重构
肾功能
血糖
低血压
heart failure
Sacubitril-valsartan
cardiac remodeling
renal function
blood glucose
low blood pressure
